Resources from the same session
4196 - Ribociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase 3b CompLEEment-1 trial
Presenter: Claudio Zamagni
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Abstract
4172 - Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program
Presenter: Junien Sirieix
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Abstract
4983 - Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients
Presenter: Mattea Reinisch
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Abstract
Poster Discussion session - Breast cancer, metastatic - Invited Discussant 293PD, 294PD and 273PD
Presenter: Caroline Schroeder
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Slides
Webcast
5618 - Balixafortide (a novel CXCR4 inhibitor) and Eribulin in HER2-neg Metastatic Breast Cancer (MBC) patients (pts): a Phase I trial
Presenter: Javier Cortes Castan
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Abstract
4464 - Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients
Presenter: Jennifer Specht
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Abstract
1741 - Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients
Presenter: MING-SHEN DAI
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Abstract
2770 - PERNETTA – A non comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)
Presenter: Jens Huober
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Abstract
5383 - Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): results from the multicohort phase II FINESSE trial
Presenter: Rina Hui
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Abstract
Poster Discussion session - Breast cancer, metastatic - Invited Discussant 288PD, 289PD and one LBA TBC
Presenter: Lisa Carey
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Slides
Webcast